ScreenerHero

ICUSeaStar Medical Holding Corporation Common Stock

NAS · US · Healthcare · Biotechnology · seastarmedical.com
3.350USD+2.45%Mkt Cap: 14.76M $P/E: —

SeaStar Medical Holding Corporation, a commercial-stage healthcare company, develops a proprietary platform therapy to reduce the consequences of hyperinflammation on vital organs in the United States. The company offers…

Industry Peers

Biotechnology
Screen all
VRTX
Vertex Pharmaceuticals Incorporated
$138.82BUSDP/E 31.9
REGN
Regeneron Pharmaceuticals, Inc.
$85.87BUSDP/E 20.5
ARGX
ARGENX SE
$61.34BUSDP/E 39.8
ARGX
argenx SE
$65.05BUSDP/E 39.6
MRNA
Moderna, Inc.
$57.94BUSD
UCB
UCB SA
$45.95BUSDP/E 19.6
RVMD
Revolution Medicines, Inc.
$44.89BUSD
ONC
BeOne Medicines AG
$42.36BUSDP/E 67.2
RPRX
Royalty Pharma Plc Class A
$35.43BUSDP/E 32.6
ALNY
Alnylam Pharmaceuticals, Inc.
$31.61BUSDP/E 41.2
BNTX
BioNTech SE
$29.28BUSD
INSM
Insmed Incorporated
$27.47BUSD
ROIV
Roivant Sciences Ltd. Common Shares
$26.22BUSD
INCY
Incyte Corporation
$25.91BUSDP/E 16.2
GMAB
Genmab A/S
$20.86BUSDP/E 26.3
GMAB
Genmab A/S
$19.26BUSDP/E 26.6
ASND
Ascendis Pharma A/S
$16.61BUSDP/E 19.6
JAZZ
Jazz Pharmaceuticals plc
$16.51BUSDP/E 17.4
BBIO
BridgeBio Pharma, Inc.
$15.93BUSD
EXEL
Exelixis, Inc.
$13.40BUSDP/E 17.0

Key Statistics

Company
Market Cap14.76M $
Enterprise Value7.89M $
Revenue (TTM)1.71M $
Gross Profit1.18M $
Net Income (TTM)-12.15M $
Revenue/Share0.4790 USD
Last Price3.350 USD
Fiscal Year EndDec 2025
MR QuarterJun 2026
Employees18
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)-1.30
PEG—
EV/EBITDA—
EV/Revenue4.61
P/S8.59
P/B1.23
EPS (TTM)-1.92
EPS (Forward)-2.57
52W Range
2.07012% of range12.50
52W High12.50 USD
52W Low2.070 USD
Profitability
Gross Margin95.71%
Oper. Margin-616.42%
EBITDA Margin0.00%
Profit Margin-984.60%
ROE-116.65%
ROA-85.82%
Growth
Revenue Growth82.00%
Earnings Growth—
Cash Flow & Leverage
Operating CF-13.60M $
CapEx (TTM)—
FCF Margin-533.63%
FCF Yield-61.92%
Net Debt-6.83M $
Net Debt/EBITDA—
Balance Sheet
Debt/Equity0.05
Current Ratio1.89
Quick Ratio1.65
Book Value/Sh2.709 USD
Cash/Share1.579 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 USD
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Splits
Last Split1:10
Split DateJan 5, 2026
Analyst Consensus
Rating2.0 (Buy)
Strong BuyBuyHoldSellStr. Sell
Target (Mean)10.00 USD
Upside (mean)+198.5%
Target Range8.000 USD – 12.00 USD
$8.000+198.5% to mean$12.00
# Analysts2
Ownership
Shares Out.4.41M
Float4.36M
Insiders11.62%
Institutions7.62%
Short Interest
Short Ratio0.9d
Short % Float2.30%
Short % Out.2.28%
Shares Short91.18K
Short (prev mo.)81.91K
Technical
SMA 503.649 (-8.2%)
SMA 2003.353 (-0.1%)
Beta-1.04
S&P 52W Chg18.16%
Avg Vol (30d)70.61K
Avg Vol (10d)87.63K
Technical Indicators
RSI (14)46.2
MACD-0.1369
MACD Signal-0.1497
MACD Hist.+0.0128
BB Upper3.800 USD
BB Middle3.338 USD
BB Lower2.875 USD
BB Width27.70%
ATR (14)0.2884 USD
Vol Ratio (20d)0.93x